Original Research2 January 2018
    Author, Article, and Disclosure Information
    Background:

    Only 1 in 5 of the nearly 2.4 million Americans with an opioid use disorder received treatment in 2015. Fewer than half of Californians who received treatment in 2014 received opioid agonist treatment (OAT), and regulations for admission to OAT in California are more stringent than federal regulations.

    Objective:

    To determine the cost-effectiveness of OAT for all treatment recipients compared with the observed standard of care for patients presenting with opioid use disorder to California's publicly funded treatment facilities.

    Design:

    Model-based cost-effectiveness analysis.

    Data Sources:

    Linked population-level administrative databases capturing treatment and criminal justice records for California (2006 to 2010); published literature.

    Target Population:

    Persons initially presenting for publicly funded treatment of opioid use disorder.

    Time Horizon:

    Lifetime.

    Perspective:

    Societal.

    Intervention:

    Immediate access to OAT with methadone for all treatment recipients compared with the observed standard of care (54.3% initiate opioid use disorder treatment with medically managed withdrawal).

    Outcome Measures:

    Discounted quality-adjusted life-years (QALYs) and discounted costs.

    Results of Base-Case Analysis:

    Immediate access to OAT for all treatment recipients costs less (by $78 257), with patients accumulating more QALYs (by 0.42) than with the observed standard of care. In a hypothetical scenario where all Californians starting treatment of opioid use disorder in 2014 had immediate access to OAT, total lifetime savings for this cohort could be as high as $3.8 billion.

    Results of Sensitivity Analysis:

    99.6% of the 2000 simulations resulted in lower costs and more QALYs.

    Limitation:

    Nonrandomized delivery of OAT or medically managed withdrawal.

    Conclusion:

    The value of publicly funded treatment of opioid use disorder in California is maximized when OAT is delivered to all patients presenting for treatment, providing greater health benefits and cost savings than the observed standard of care.

    Primary Funding Source:

    National Institute on Drug Abuse.

    References

    • 1. Jones CMCampopiano MBaldwin GMcCance-Katz ENational and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health2015;105:e55-63. [PMID: 26066931] doi:10.2105/AJPH.2015.302664 CrossrefMedlineGoogle Scholar
    • 2. Murthy VHEnding the opioid epidemic—a call to action. N Engl J Med2016;375:2413-5. [PMID: 27959718] doi:10.1056/NEJMp1612578 CrossrefMedlineGoogle Scholar
    • 3. Substance Abuse and Mental Health Services AdministrationKey Substance Use and Mental Health Indicators in the United States: Results From the 2015 National Survey on Drug Use and Health. Rockville: Substance Abuse and Mental Health Services Administration; 2016. Google Scholar
    • 4. Saloner BKarthikeyan SChanges in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004-2013. JAMA2015;314:1515-7. [PMID: 26462001] doi:10.1001/jama.2015.10345 CrossrefMedlineGoogle Scholar
    • 5. Center for Behavioral Health Statistics and Quality. Treatment episode data set (TEDS): 2005-2015. State admissions to substance abuse treatment services. July 2017. Accessed at https://wwwdasis.samhsa.gov/dasis2/teds_pubs/2015_teds_rpt_st.pdf on 28 June 2017. Google Scholar
    • 6. World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. 2009. Accessed at http://apps.who.int/iris/handle/10665/43948 on 5 July 2017. Google Scholar
    • 7. Mattick RPBreen CKimber JDavoli MMethadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev2009:CD002209. [PMID: 19588333] doi:10.1002/14651858.CD002209.pub2 CrossrefMedlineGoogle Scholar
    • 8. Office of the Surgeon General. Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health. Washington, DC: U.S. Department of Health and Human Services; 2016. Accessed at https://addiction.surgeongeneral.gov/surgeon-generals-report.pdf on 2 July 2017. Google Scholar
    • 9. Schuckit MATreatment of opioid-use disorders. N Engl J Med2016;375:357-68. [PMID: 27464203] doi:10.1056/NEJMra1604339 CrossrefMedlineGoogle Scholar
    • 10. Stephenson DKCalifornia Society of Addiction Medicine Committee on Treatment of Opioid DependenceGuideline for Physicians Working in California Opioid Treatment Programs. San Francisco: California Society of Addiction Medicine; 2008:1-152. Google Scholar
    • 11. Nosyk BLi LEvans EUrada DHuang DWood Eet alUtilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, USA: 1991-2012. Drug Alcohol Depend2014;143:149-57. [PMID: 25110333] doi:10.1016/j.drugalcdep.2014.07.020 CrossrefMedlineGoogle Scholar
    • 12. McLellan ATLewis DCO'Brien CPKleber HDDrug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA2000;284:1689-95. [PMID: 11015800] CrossrefMedlineGoogle Scholar
    • 13. Evans ELi LMin JHuang DUrada DLiu Let alMortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10. Addiction2015;110:996-1005. [PMID: 25644938] doi:10.1111/add.12863 CrossrefMedlineGoogle Scholar
    • 14. Krebs EMin JEEvans ELi LLiu LHuang Det alEstimating state transitions for opioid use disorders. Med Decis Making2017;37:483-97. [PMID: 28027027] doi:10.1177/0272989X16683928 CrossrefMedlineGoogle Scholar
    • 15. Centers for Disease Control and Prevention. AtlasPlus: persons living with diagnosed HIV. 2016. Accessed at https://gis.cdc.gov/grasp/nchhstpatlas/main.html?value=AQT on 28 June 2017. Google Scholar
    • 16. Nosyk BGuh DPBansback NJOviedo-Joekes EBrissette SMarsh DCet alCost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. CMAJ2012;184:E317-28. doi:10.1503/cmaj.110669 CrossrefMedlineGoogle Scholar
    • 17. Krebs EUrada DEvans EHuang DHser YINosyk BThe costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California. Addiction2017;112:838-51. [PMID: 27981691] doi:10.1111/add.13729 CrossrefMedlineGoogle Scholar
    • 18. Zarkin GADunlap LJHicks KAMamo DBenefits and costs of methadone treatment: results from a lifetime simulation model. Health Econ2005;14:1133-50. [PMID: 15880389] CrossrefMedlineGoogle Scholar
    • 19. Los Angeles County Department of Public Health. 2014 Annual HIV/STD Surveillance Report. Los Angeles: Los Angeles County Department of Public Health; 2016. Accessed at http://publichealth.lacounty.gov/dhsp/Reports/HIV-STDsurveillanceReport2014.pdf on 28 June 2017. Google Scholar
    • 20. Nosyk BLi LEvans EHuang DMin JKerr Tet alCharacterizing longitudinal health state transitions among heroin, cocaine, and methamphetamine users. Drug Alcohol Depend2014;140:69-77. [PMID: 24837584] doi:10.1016/j.drugalcdep.2014.03.029 CrossrefMedlineGoogle Scholar
    • 21. Springborn RR. Abridged life tables for California, 2004. Center for Health Statistics. 2006. Accessed at www.dhcs.ca.gov/services/ltc/Documents/lifetables2004.pdf on 28 June 2017. Google Scholar
    • 22. Zlotorzynska MSpaulding ACMessina LCCoker DWard KEasley Ket alRetrospective cohort study of cancer incidence and mortality by HIV status in a Georgia, USA, prisoner cohort during the HAART era. BMJ Open2016;6:e009778. [PMID: 27067888] doi:10.1136/bmjopen-2015-009778 CrossrefMedlineGoogle Scholar
    • 23. Bayoumi AMZaric GSThe cost-effectiveness of Vancouver's supervised injection facility. CMAJ2008;179:1143-51. [PMID: 19015565] doi:10.1503/cmaj.080808 CrossrefMedlineGoogle Scholar
    • 24. Gough EKempf MCGraham LManzanero MHook EWBartolucci Aet alHIV and hepatitis B and C incidence rates in US correctional populations and high risk groups: a systematic review and meta-analysis. BMC Public Health2010;10:777. [PMID: 21176146] doi:10.1186/1471-2458-10-777 CrossrefMedlineGoogle Scholar
    • 25. Nosyk BBray JWWittenberg EAden BEggman AAWeiss RDet alShort term health-related quality of life improvement during opioid agonist treatment. Drug Alcohol Depend2015;157:121-8. [PMID: 26511766] doi:10.1016/j.drugalcdep.2015.10.009 CrossrefMedlineGoogle Scholar
    • 26. Fryback DGDunham NCPalta MHanmer JBuechner JCherepanov Det alUS norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Med Care2007;45:1162-70. [PMID: 18007166] CrossrefMedlineGoogle Scholar
    • 27. Chong CALi SNguyen GCSutton ALevy MHButler Tet alHealth-state utilities in a prisoner population: a cross-sectional survey. Health Qual Life Outcomes2009;7:78. [PMID: 19715571] doi:10.1186/1477-7525-7-78 CrossrefMedlineGoogle Scholar
    • 28. Aden BDunning ANosyk BWittenberg EBray JWSchackman BRImpact of illicit drug use on health-related quality of life in opioid-dependent patients undergoing HIV treatment. J Acquir Immune Defic Syndr2015;70:304-10. [PMID: 26218410] doi:10.1097/QAI.0000000000000768 CrossrefMedlineGoogle Scholar
    • 29. Gebo KAFleishman JAConviser RHellinger JHellinger FJJosephs JSet alHIV Research NetworkContemporary costs of HIV healthcare in the HAART era. AIDS2010;24:2705-15. [PMID: 20859193] doi:10.1097/QAD.0b013e32833f3c14 CrossrefMedlineGoogle Scholar
    • 30. Polsky DGlick HAYang JSubramaniam GAPoole SAWoody GECost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial. Addiction2010;105:1616-24. [PMID: 20626379] doi:10.1111/j.1360-0443.2010.03001.x CrossrefMedlineGoogle Scholar
    • 31. Mohlman MKTanzman BFinison KPinette MJones CImpact of medication-assisted treatment for opioid addiction on Medicaid expenditures and health services utilization rates in Vermont. J Subst Abuse Treat2016;67:9-14. [PMID: 27296656] doi:10.1016/j.jsat.2016.05.002 CrossrefMedlineGoogle Scholar
    • 32. Baser OXie LMardekian JSchaaf DWang LJoshi AVPrevalence of diagnosed opioid abuse and its economic burden in the Veterans Health Administration. Pain Pract2014;14:437-45. [PMID: 23809020] doi:10.1111/papr.12097 CrossrefMedlineGoogle Scholar
    • 33. Cuckler GMartin AWhittle LHeffler SSisko ALassman Det alHealth spending by state of residence, 1991-2009. Medicare Medicaid Res Rev2011;1. [PMID: 22340779] doi:10.5600/mmrr.001.04.a03 CrossrefMedlineGoogle Scholar
    • 34. Tookes HDiaz CLi HKhalid RDoblecki-Lewis SA cost analysis of hospitalizations for infections related to injection drug use at a county safety-net hospital in Miami, Florida. PLoS One2015;10:e0129360. [PMID: 26075888] doi:10.1371/journal.pone.0129360 CrossrefMedlineGoogle Scholar
    • 35. Krebs EKerr TMontaner JWood ENosyk BDynamics in the costs of criminality among opioid dependent individuals. Drug Alcohol Depend2014;144:193-200. [PMID: 25282307] doi:10.1016/j.drugalcdep.2014.09.007 CrossrefMedlineGoogle Scholar
    • 36. Legislative Analyst's Office. How much does it cost to incarcerate an inmate? California's annual cost to incarcerate an inmate in prison 2016-17. Updated March 2017. Accessed at www.lao.ca.gov/PolicyAreas/CJ/6_cj_inmatecost on 28 June 2017. Google Scholar
    • 37. Sanders GDNeumann PJBasu ABrock DWFeeny DKrahn Met alRecommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second Panel on Cost-Effectiveness in Health and Medicine. JAMA2016;316:1093-103. [PMID: 27623463] doi:10.1001/jama.2016.12195 CrossrefMedlineGoogle Scholar
    • 38. Siebert UAlagoz OBayoumi AMJahn BOwens DKCohen DJet alISPOR-SMDM Modeling Good Research Practices Task ForceState-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force—3. Value Health2012;15:812-20. [PMID: 22999130] doi:10.1016/j.jval.2012.06.014 CrossrefMedlineGoogle Scholar
    • 39. Bovasso GCacciola JThe long-term outcomes of drug use by methadone maintenance patients. J Behav Health Serv Res2003;30:290-303. [PMID: 12875097] CrossrefMedlineGoogle Scholar
    • 40. Hser YILongshore DAnglin MDThe life course perspective on drug use: a conceptual framework for understanding drug use trajectories. Eval Rev2007;31:515-47. [PMID: 17986706] CrossrefMedlineGoogle Scholar
    • 41. Termorshuizen FKrol APrins MGeskus Rvan den Brink Wvan Ameijden EJPrediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. Drug Alcohol Depend2005;79:231-40. [PMID: 16002032] CrossrefMedlineGoogle Scholar
    • 42. Degenhardt LBucello CMathers BBriegleb CAli HHickman Met alMortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction2011;106:32-51. [PMID: 21054613] doi:10.1111/j.1360-0443.2010.03140.x CrossrefMedlineGoogle Scholar
    • 43. R Core TeamR: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2016. Google Scholar
    • 44. Substance Abuse and Mental Health Services Administration. 2013 state profile—California. National Survey of Substance Abuse Treatment Services (N-SSATS). 2015. Accessed at https://wwwdasis.samhsa.gov/webt/newmapv1.htm on 28 June 2017. Google Scholar
    • 45. Nosyk BMacNab YCSun HFischer BMarsh DCSchechter MTet alProportional hazards frailty models for recurrent methadone maintenance treatment. Am J Epidemiol2009;170:783-92. [PMID: 19671835] doi:10.1093/aje/kwp186 CrossrefMedlineGoogle Scholar
    • 46. Caro JJBriggs AHSiebert UKuntz KMISPOR-SMDM Modeling Good Research Practices Task ForceModeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making2012;32:667-77. [PMID: 22990082] CrossrefMedlineGoogle Scholar
    • 47. Garrison LPMansley ECAbbott TABresnahan BWHay JWSmeeding JGood research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report—part II. Value Health2010;13:8-13. [PMID: 19883405] doi:10.1111/j.1524-4733.2009.00660.x CrossrefMedlineGoogle Scholar
    • 48. Husereau DDrummond MPetrou SCarswell CMoher DGreenberg Det alISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task ForceConsolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health2013;16:231-50. [PMID: 23538175] doi:10.1016/j.jval.2013.02.002 CrossrefMedlineGoogle Scholar
    • 49. Substance Abuse and Mental Health Services Administration. Treatment episode data set—admissions (TEDS-A), 2014. 2016. Accessed at https://wwwdasis.samhsa.gov/dasis2/teds.htm on 28 June 2017. Google Scholar
    • 50. Broz D, Wejnert C, Pham HT, DiNenno E, Heffelfinger JD, Cribbin M, et al. HIV infection and risk, prevention, and testing behaviors among injecting drug users—National HIV Behavioral Surveillance System, 20 US cities, 2009. 2014. Accessed at www.cdc.gov/mmwr/preview/mmwrhtml/ss6306a1.htm on 24 February 2017. Google Scholar
    • 51. Amato LMinozzi SDavoli MVecchi SFerri MMMayet SPsychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev2008:CD005031. [PMID: 18843675] doi:10.1002/14651858.CD005031.pub3 CrossrefMedlineGoogle Scholar
    • 52. Nosyk BAnglin MDBrissette SKerr TMarsh DCSchackman BRet alA call for evidence-based medical treatment of opioid dependence in the United States and Canada. Health Aff (Millwood)2013;32:1462-9. [PMID: 23918492] doi:10.1377/hlthaff.2012.0846 CrossrefMedlineGoogle Scholar
    • 53. O'Connor PGMethods of detoxification and their role in treating patients with opioid dependence [Editorial]. JAMA2005;294:961-3. [PMID: 16118388] CrossrefMedlineGoogle Scholar
    • 54. Substance Abuse and Mental Health Services Administration. Federal Guidelines for Opioid Treatment Programs. Rockville: Substance Abuse and Mental Health Services Administration; 2015. Accessed at https://store.samhsa.gov/shin/content/PEP15-FEDGUIDEOTP/PEP15-FEDGUIDEOTP.pdf on 28 June 2017. Google Scholar
    • 55. Dowell DHaegerich TMChou RCDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA2016;315:1624-45. [PMID: 26977696] doi:10.1001/jama.2016.1464 CrossrefMedlineGoogle Scholar
    • 56. Medical Board of California. Guidelines for prescribing controlled substances for pain. November 2014. Accessed at www.mbc.ca.gov/Licensees/Prescribing/Pain_Guidelines.pdf on 28 June 2017. Google Scholar
    • 57. Office of the Press Secretary; the White HousePresident Obama proposes $1.1 billion in new funding to address the prescription opioid abuse and heroin use epidemic. J Pain Palliat Care Pharmacother2016;30:134-7. [PMID: 27301690] doi:10.3109/15360288.2016.1173760 CrossrefMedlineGoogle Scholar
    • 58. Jones CMLogan JGladden RMBohm MKVital signs: demographic and substance use trends among heroin users—United States, 2002-2013. MMWR Morb Mortal Wkly Rep2015;64:719-25. [PMID: 26158353] MedlineGoogle Scholar
    • 59. Abraham AJAndrews CMGrogan CMD'Aunno THumphreys KNPollack HAet alThe Affordable Care Act transformation of substance use disorder treatment. Am J Public Health2017;107:31-2. [PMID: 27925819] CrossrefMedlineGoogle Scholar
    • 60. Saloner BBandara SBachhuber MBarry CLInsurance coverage and treatment use under the Affordable Care Act among adults with mental and substance use disorders. Psychiatr Serv2017;68:542-8. [PMID: 28093059] doi:10.1176/appi.ps.201600182 CrossrefMedlineGoogle Scholar
    • 61. Health Resources and Services Administration; HIV/AIDS Bureau. About the Ryan White HIV/AIDS Program. 2017. Accessed at https://hab.hrsa.gov/about-ryan-white-hivaids-program/about-ryan-white-hivaids-program on 28 June 2017. Google Scholar
    • 62. Williams ARBisaga AFrom AIDS to opioids—how to combat an epidemic. N Engl J Med2016;375:813-5. [PMID: 27579632] doi:10.1056/NEJMp1604223 CrossrefMedlineGoogle Scholar
    • 63. 21st Century Cures Act, H.R. 34, 114th Cong. (2015). Google Scholar
    • 64. Sculpher MJClaxton KDrummond MMcCabe CWhither trial-based economic evaluation for health care decision making? Health Econ2006;15:677-87. [PMID: 16491461] CrossrefMedlineGoogle Scholar
    • 65. Weinstein MCO'Brien BHornberger JJackson JJohannesson MMcCabe Cet alISPOR Task Force on Good Research Practices—Modeling StudiesPrinciples of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health2003;6:9-17. [PMID: 12535234] CrossrefMedlineGoogle Scholar
    • 66. Zaric GSBarnett PGBrandeau MLHIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health2000;90:1100-11. [PMID: 10897189] CrossrefMedlineGoogle Scholar
    • 67. Doran CMEconomic evaluation of interventions to treat opiate dependence: a review of the evidence. Pharmacoeconomics2008;26:371-93. [PMID: 18429655] CrossrefMedlineGoogle Scholar
    • 68. Murphy SMPolsky DEconomic evaluations of opioid use disorder interventions. Pharmacoeconomics2016;34:863-87. [PMID: 27002518] doi:10.1007/s40273-016-0400-5 CrossrefMedlineGoogle Scholar
    • 69. Dijkgraaf MGvan der Zanden BPde Borgie CABlanken Pvan Ree JMvan den Brink WCost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. BMJ2005;330:1297. [PMID: 15933353] CrossrefMedlineGoogle Scholar
    • 70. Andrews CMD'Aunno TAPollack HAFriedmann PDAdoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs. Med Care Res Rev2014;71:43-60. [PMID: 24051897] doi:10.1177/1077558713503188 CrossrefMedlineGoogle Scholar
    • 71. Deck DWiitala WMcFarland BCampbell KMullooly JKrupski Aet alMedicaid coverage, methadone maintenance, and felony arrests: outcomes of opiate treatment in two states. J Addict Dis2009;28:89-102. [PMID: 19340671] doi:10.1080/10550880902772373 CrossrefMedlineGoogle Scholar
    • 72. Barua SGreenwald RGrebely JDore GJSwan TTaylor LERestrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med2015;163:215-23. [PMID: 26120969]. doi:10.7326/M15-0406 LinkGoogle Scholar
    • 73. Harris MRhodes THepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J2013;10:7. [PMID: 23651646] doi:10.1186/1477-7517-10-7 CrossrefMedlineGoogle Scholar